IQVIA Holdings Inc. (IQV) Fundamental Analysis: Bull vs. Bear Case

IQV

IQVIA Holdings Inc.

Fundamental data last updated:July 3, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NYSE

County of HQ

US

Next Earnings Date

07/28/2026

Business Summary

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

VALUATION

P/E

22.11 Market Cap ($M USD)

$30.36B

Forward P/E

9.31 PEG

0.07 PRICE TO SALES

1.83 PRICE TO BOOK

4.92 EV / EBITDA

8.68 5-Year Average P/E

Free Cash Flow Yield

8.80%

DCF Value

$285.76

Graham Number

$82.68

Price to FCF

11.36 EV to FCF

11.41 Earnings Yield

4.52%

FCF Yield

8.80%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$8.22

Next Year EPS Growth Estimate

$19.53

Next Year Revenue Growth Estimate

$2.14T

Return on Equity (ROE)

22.46%

FREE CASH FLOW

Operating Margin

13.86%

Debt-to-Equity

2.49 Piotroski F-Score

6 Altman Z-Score

1.80 Return on Invested Capital (ROIC)

10.80%

Current Ratio

0.75 Quick Ratio

0.75 Net Debt to EBITDA

0.04 Interest Coverage

3.05 Gross Profit margin

26.11%

FCF PER SHARE

$15.87

REVENUE PER SHARE

$98.76

Gainseekers Quantitative Analysis

Summary

IQVIA Holdings Inc. presents a compelling valuation story. The stock has traded below its DCF value, suggesting a potential mispricing by the market. With a Forward P/E of 9.11 and a PEG ratio of 0.07, the company appears undervalued relative to its growth prospects. However, the Altman Z-score of 1.87 raises concerns about financial stability, indicating a need for cautious optimism. The Earnings Yield of 4.60% further supports the notion of a potentially attractive investment, but investors should weigh these factors against the company’s debt profile.

AI Exposure / Tech Reliance

Operating in the Medical - Diagnostics & Research industry, IQVIA is well-positioned to leverage AI and modern technology. The healthcare sector's increasing reliance on data analytics and diagnostics aligns with IQVIA's core competencies. This positioning could enhance its resilience and adaptability in a rapidly evolving tech landscape.

The Bull Case

For the value-driven investor, IQVIA offers a robust case. With a ROIC of 10.80%, the company demonstrates efficient capital allocation, translating into solid returns. The FCF Yield of 8.96% underscores its ability to generate cash, while a Piotroski F-Score of 6 suggests reasonable financial health. Its operating margin of 13.86% indicates strong pricing power, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, IQVIA faces notable challenges. The Price/Book ratio of 4.84 and Price/Sales ratio of 1.79 suggest a premium valuation, potentially limiting upside. The Altman Z-score indicates financial vulnerability, and a Current Ratio of 0.75 highlights liquidity concerns. Additionally, trading at a significant distance from its 52-week low, the stock may be technically overextended, warranting caution.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$223.75

Institutional Ownership %

1-Year Beta

1.18 Insider Buying % (6 Mo)

Distance to 52-Week High

35.83%

Distance to 52-Week Low

25.00%

EARNINGS SURPRISE %

2.84%

50-DAY SMA

$169.56

200-DAY SMA

$195.94

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.